KYMR Kymera Therapeutics, Inc.

119.39USD-1.44%Mkt Cap: 10.19B USDP/E: —

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natu…

Insiders, last 90 daysNet sellers
Institutional holders20 on file

Key Statistics

Company
Market Cap10.19B USD
Enterprise Value9.45B USD
Revenue (TTM)102.23M USD
Gross Profit-327.75M USD
Net Income (TTM)-311.35M USD
Revenue/Share1.06 USD
Last Price119.39 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees285
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-23.33
PEG—
EV/EBITDA-23.71
EV/Revenue92.40
P/S99.70
P/B6.31
EPS (TTM)-3.64 USD
EPS (Forward)-5.12 USD
52W Range
56.7573% of range142.92
52W High142.92 USD
52W Low56.75 USD
Profitability
Gross Margin0.00%
Oper. Margin-396.04%
EBITDA Margin0.00%
Profit Margin-794.04%
ROE-19.71%
ROA-17.86%
ROIC-33.55%
ROCE-20.82%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-232.89M USD
CapEx (TTM)1.45M USD
FCF Margin-161.08%
FCF Yield-1.62%
Net Debt-894.62M USD
Net Debt/EBITDA2.25
Net Debt/FCF—
Balance Sheet
Debt/Equity0.05
Current Ratio11.13
Quick Ratio10.82
Book Value/Sh18.92 USD
Cash/Share11.38 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)145.22 USD
Upside (mean)+21.6%
Target Range116.00 USD – 180.00 USD
116.00+21.6% to mean180.00
# Analysts23
Ownership
Shares Out.85.37M
Float68.26M
Insiders2.07%
Institutions116.12%
Short Interest
Short Ratio9.5d
Short % Float12.57%
Short % Out.9.84%
Shares Short8.40M
Short (prev mo.)9.91M
Technical
SMA 50117.30 (+1.8%)
SMA 20099.71 (+19.7%)
Beta2.03
S&P 52W Chg12.08%
Avg Vol (30d)914.62K
Avg Vol (10d)1.10M
Technical Indicators
RSI (14)45.5
MACD2.1431
MACD Signal3.8447
MACD Hist.-1.7016
BB Upper140.77 USD
BB Middle125.93 USD
BB Lower111.09 USD
BB Width23.57%
ATR (14)6.561 USD
Vol Ratio (20d)0.74x

About Kymera Therapeutics (NASDAQ: KYMR)

›

Kymera Therapeutics (NASDAQ: KYMR) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 285 employees.

The shares were at 119.39 USD on 19 November 2026, up 95.7% over 52 weeks. Its 52-week range is 56.75 USD to 142.92 USD: the price is 16.5% below the high and 110.4% above the low.

Its market capitalisation is 10.19B USD.

Kymera Therapeutics reports return on equity of -19.7% and an operating margin of -396.0%.

It holds more cash than debt, a net cash position of 894.62M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 23 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 145.22 USD is 21.6% above the current price. The next earnings report is expected on 25 February 2027.